SequelSEC

BIOGEN INC. BIIB

Biological Products, (No Diagnostic Substances) · CIK 0000875045 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$2.48B
Fiscal year ended 2026-03-31
Operating income
Unavailable
Fiscal year ended 2026-03-31
Free cash flow
$594.30M
Fiscal year ended 2026-03-31

BIOGEN INC. (BIIB) reported revenue of $2.48B and net income of $319.50M for the fiscal year ended 2026-03-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BIOGEN INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

BIOGEN INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Revenue$2.48B$2.28B$2.53B$2.65B$2.43B$2.45B$2.47B$2.46B$2.29B$2.39B
Cost of revenue$661.00M$495.50M$674.40M$605.00M$629.30M$583.50M$638.70M$546.00M$542.20M$618.30M
Gross profit$1.82B$1.78B$1.86B$2.04B$1.80B$1.87B$1.83B$1.92B$1.75B$1.77B
Operating incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net income$319.50M-$48.90M$466.50M$634.80M$240.50M$266.70M$388.50M$583.60M$393.40M$249.70M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 148.40MUnavailableshares 147.10Mshares 146.70Mshares 146.60MUnavailableshares 146.10Mshares 145.90Mshares 145.90MUnavailable
Pretax income$377.70M-$56.00M$557.30M$744.00M$311.20M$291.50M$451.00M$698.70M$464.80M$291.60M
Income tax expense$58.20M-$7.10M$90.80M$109.20M$70.70M$24.80M$62.50M$115.10M$71.40M$42.70M
Diluted EPS$2.15Unavailable$3.17$4.33$1.64Unavailable$2.66$4.00$2.70Unavailable
Selling, general & administrative$607.30M$682.50M$594.80M$583.80M$572.50M$680.00M$588.40M$553.80M$581.50M$608.50M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

BIOGEN INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Cash & equivalentsUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Total assets$29.48B$29.44B$29.21B$28.33B$28.03B$28.05B$28.31B$26.80B$26.57B$26.84B
Current assets$9.19B$8.97B$8.94B$7.97B$7.63B$7.46B$6.83B$7.11B$6.76B$6.86B
Total liabilities$10.83B$11.18B$11.00B$10.70B$11.05B$11.33B$11.95B$10.92B$11.35B$12.05B
Current liabilities$3.00B$3.35B$3.29B$3.18B$5.30B$5.53B$5.42B$3.11B$3.22B$3.43B
Total equity incl. NCI$18.65B$18.26B$18.21B$17.63B$16.98B$16.72B$16.36B$15.89B$15.21B$14.80B
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$1.95B$2.17B$2.21B$2.27B$2.27B$2.46B$2.47B$2.51B$2.52B$2.53B
Accounts receivableUnavailable$1.34BUnavailableUnavailableUnavailable$1.40BUnavailableUnavailableUnavailable$1.66B
Goodwill$6.49B$6.49B$6.49B$6.49B$6.48B$6.48B$6.49B$6.23B$6.23B$6.22B
Long-term debt$6.29B$6.29B$6.29B$6.28B$4.55B$4.55B$4.55B$6.29B$6.29B$6.79B
Accounts payable$358.50M$432.00M$413.10M$408.40M$391.50M$424.20M$422.70M$354.50M$387.00M$403.30M

Cash flow

BIOGEN INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Operating cash flow$645.50M$511.90M$1.27B$160.90M$259.30M$760.90M$935.60M$625.80M$553.20M$12.50M
Capital expenditures$51.20M$43.90M$46.20M$26.60M$37.10M$39.30M$35.00M$33.50M$45.90M$65.20M
Investing cash flow-$209.50M-$1.23B-$35.10M-$57.00M-$47.30M-$18.60M-$1.18B$466.50M-$66.00M-$652.30M
Financing cash flow-$43.80M-$137.00M-$130.20M-$11.70M-$23.00M$7.90M-$6.60M-$245.20M-$439.60M-$646.10M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$84.00M$59.60M$75.30M$74.90M$81.00M$75.10M$72.70M$70.60M$72.80M$54.90M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0
Depreciation & amortization$204.40M$200.20M$202.20M$194.30M$183.20M$184.00M$182.80M$158.90M$147.50M$140.10M

Derived

BIOGEN INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Free cash flow$594.30M$468.00M$1.23B$134.30M$222.20M$721.60M$900.60M$592.30M$507.30M-$52.70M
Gross margin73.3%78.3%73.4%77.1%74.1%76.2%74.1%77.8%76.3%74.1%
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF margin24.0%20.5%48.4%5.1%9.1%29.4%36.5%24.0%22.1%-2.2%
SBC / revenue3.4%2.6%3.0%2.8%3.3%3.1%2.9%2.9%3.2%2.3%
Current ratio3.06x2.68x2.72x2.50x1.44x1.35x1.26x2.29x2.10x2.00x
Revenue YoY growth1.9%-7.1%2.8%7.3%6.1%2.9%-2.5%0.4%-7.0%-6.2%
Net margin12.9%-2.1%18.4%24.0%9.9%10.9%15.8%23.7%17.2%10.5%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue2.1%1.9%1.8%1.0%1.5%1.6%1.4%1.4%2.0%2.7%
Long-term debt / equity0.34x0.34x0.35xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate15.4%Unavailable16.3%14.7%22.7%8.5%13.9%16.5%15.4%14.6%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BIIB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-04-29View SEC filing
10-K · Filed 2026-02-06View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-05-01View SEC filing
10-K · Filed 2025-02-12View SEC filing

Companies in the same industry

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationinconsistent2022-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2022-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.